Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment
Tóm tắt
Angiogenesis plays fundamentally critical roles in solid-tumor pathogenesis, growth, invasion and metastasis. Endostatin, one of the most potent anti-angiogenic factors, was first isolated in Folkman’s lab in 1997, and was reported to dramatically shrink tumor blood formation. But its insoluble and unstable nature coupled with the high cost of synthesizing the endostatin protein doomed it for clinical cancer treatment. Intrigued by Folkman’s pioneering discoveries, Chinese scientists found a way to refold the protein, making it cost-effective to manufacture a recombinant human endostatin, a soluble and stable form of endostatin. A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma (NSCLC) and, as a result, rh-endostatin (Endostar®) was approved by the State Food and Drug Administration of China (CFDA) in September of 2005 as a treatment option for NSCLC. Since then, increasing bodies of clinical data and experience have been obtained from a variety of other different cancers, such as small cell lung cancer, NSCLC in other settings, including malignant serous effusion, melanoma, colon cancer, gastric cancer, breast cancer, nasopharyngeal cancers, and others. This review aims at summarizing current clinical data of rh-endostatin including its survival benefits, optimized dosages, routes of administration, recommended duration and frequency of treatment, predictive biomarkers, and its safety profile in lung cancers as well as other cancers.
Tài liệu tham khảo
Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49.
O’Reilly MS, Boehm T, Shing Y, Fukar N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85.
Fu Y, Tang H, Huang Y, et al. Unraveling the mysteries of endostatin. IUBMB Life. 2009;61(6):613–26.
Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev. 2014;40(4):548–57.
Walia A, Yang JF, Huang YH, et al. Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications[J]. Biochim Biophys Acta. 2015;1850(12):2422–38.
Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390(6658):404–7.
Fukumoto S, Morifuji M, Katakura Y, Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis. 2005;22(1):31–8.
Liu BD, Zhi XY. Evaluation of local curative effect of image—guided thermal ablation in the treatment of lung. Chin J Front Med Sci. 2015;2:11–4.
Sun Y, Wang JW, Liu YY, Yu QT, Zhang YP, Li K, et al. Long term results of a randomized, double-blind, and placebo controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer. Thorac Cancer. 2013;4(4):440–8.
Wang J, Sun Y, Qin S, Endostar Phase IV Study Group. Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28(suppl; abstr 7598):15s.
Han B, Xiu Q, Wang H, Shen J, Gu AQ, Luo Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(6):1104–9.
Wang J, Li K, Sun T, Zhang MJ, Li WL, Yao Q, et al. The efficacy and safety of docetaxel combined with recombinant human endostatin in the treatment of non-small cell lung cancer with or without intolerance after treatment. Chin J Oncol. 2013;35(8):618–22.
Jiang XD, Ding MH, Qiao Y, Liu Y, Liu L. Study on lung cancer cells expressing VEGFR2 and the impact on the effect of RHES combined with radiotherapy in the treatment of brain metastases. Clin Lung Cancer. 2014;15(2):e23–9.
Zhang R, Wang ZY, Li YH, Lu YH, Wang S, Yu WX, et al. Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer. Am J Cancer Res. 2016;6(12):2890–900.
Jiang XD, Dai P, Wu J, Song DA, Yu JM. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(4):1272–7.
Bao Y, Peng F, Zhou QC, Yu ZH, Li JC, Cheng ZB, et al. Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Radiother Oncol. 2015;114(2):161–6.
Ma HL, Hui ZG, Zhao LJ, Xu YJ, Zhai YR, Wu RY, et al. Treatment of non-resectable stage III NSCLC with continuous intravenous injection of Endostar: results from a phase II prospective multicenter clinical trial results. Chin J Radiat Oncol. 2016;25(2):114–8.
Yang YZ, Pan LK, Qi DL, Xin L, Cui Y, An GY, et al. Effect of recombinant human endostatin combined with TP regimen on postoperative adjuvant therapy for non-small cell lung cancer. Med J Chin Lib Army. 2012;37(1):49–53.
Zhao J, Wang W, Shang LQ, Xiao W, Li XC, Song WA, et al. Comparison of postoperative adjuvant chemotherapy with combined adjuvant chemotherapy and non-small cell lung cancer. Transl Med J. 2014;3(1):19–21.
Pan F, Gu AQ, Wang WM, Jiang LY. Effect of recombinant human endostatin combined with platinum-based postoperative adjuvant chemotherapy on non-small cell lung cancer. World Clin Drugs. 2015;5:322–6.
Zhou ZT, Zhou FX, Wei Q, Zou LY, Qin BF, Peng XS. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68(4):1027–32.
Lu S, Li L, Luo Y, Zhang L, Wu G, Chen ZW, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10(1):206–11.
Chen JH, Luo YZ, Zhou WW, Zhou H, Wang W. Clinical observation of recombinant human endostatin combined with carboplatin and etoposide in the treatment of advanced small cell lung cancer. J Clin Med Pract. 2013;17(5):26–8.
Qin SK, Yang LQ, Liang J, Cheng Y, Tan QH, Bi JW, et al. Intraventricular application of recombinant human endostatin and/or cisplatin in the treatment of malignant pleural effusion of the prospective, randomized, national multi-center clinical study. Chin Clin Oncol. 2017;22(3):193–202.
Zhou JF, Bai CM, Wang YZ, et al. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study [J]. Chin Med J (Engl). 2011;124(24):4299–303.
Xu HX, Huang XE, Qian ZY, Xu X, Li Y, Li CG. Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev. 2011;12(11):3087–90.
Li BL, Hu XL, Zhao XH, Sun HG, Zhou CY, Zhang Y. Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical study. J Chemother. 2015;27(5):301–6.
Chen Z, Guo W, Cao J, Lv F, Zhang W, Qiu L, et al. Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cancer Chemother Pharmacol. 2015;75(3):547–57.
Pan YQ, Jiao GL. A meta-analysis of the short-term efficacy of degrading combined with chemotherapy in the treatment of advanced colorectal. J South Med Univ. 2014;2:270–4.
Qi XY, Yu ZY, Ouyang XN, Wang WW. Clinical observation of recombinant human vascular endostatin combined with chemotherapy in the treatment of advanced metastatic colorectal cancer. J Mod Oncol. 2015;17:2459–63.
Guo YB, Zhen L, Zhu WR, Xu X, Li Y, Li CG. Clinical observation of recombinant human endostatin combined with chemotherapy in the treatment of metastatic colorectal cancer. Chin Clin Oncol. 2011;16(8):742–5.
Cui C, Mao L, Chi Z, Si L, Sheng XN, Kong Y, et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther. 2013;21(7):1456–63.
Cui C, Si L, Chi Z, Sheng XN, Mao LL, Wang X, et al. Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma. J Clin Oncol. 2015 (suppl; abstre20087).
Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, et al. Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther. 2013;6:925–9.
Qu XL, Chai NX, Wang YJ, Han Y, Zhang Y, Tao L. Recombinant human endostatin combined with DCF regimen for neoadjuvant chemotherapy patients with advanced gastric cancer to improve the rate of radical surgery. Tumor. 2011;31(8):765–7.
Su H, Hu B, Ji CS, He YF, Han XH, Lv YJ. Meta analysis of recombinant human endostatin combined with chemotherapy in the treatment of advanced gastric cancer. Tumor. 2015;35(3):322–32.
Jin T, Li B, Chen XZ. A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286). Oncol Res. 2013;21(6):317–23.
Guan Y, Li A, Xiao W, Liu S, Chen B, Lu T, et al. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget. 2015;6(32):33926–34.
Du HJ. Clinical application of recombinant human endostatin combined with transcatheter arterial chemoembolization in the treatment of advanced liver cancer. J Interv Radiol. 2009;18(4):302–5.
Su Y, Zhou ZH, Wang Q. Efficacy and safety of recombinant human endostatin in the treatment of advanced liver cancer by transcatheter arterial chemoembolization. J Pract Hepatol. 2014;6:644–6.
Lin Q, Zhang SY, Huang N, Su YH. Meta-analysis of recombinant human endostatin injection combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma. World Chin J Digestol. 2015;4:655–64.
Jia Q, Xu J, Jiang W, et al. Dynamic contrastenhanced MR imaging in a phase II study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer [J]. Int J Med Sci. 2013;10(2):110–18.
Lu Y, Huang HX, Li GS. Clinical study of endostatin combined with GP regimen in the treatment of metastatic triple-negative breast cancer. Chin J Clin Oncol. 2012;39(23):1946–8.
Huang W, Liu J, Wu F, Chen K, Li N, Hong Y, et al. The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients. Oncotarget. 2016;7(21):31501–7.
Zhong Z, Gu X, Zhang Z, Wang D, Qing Y, Li M, et al. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. Br J Radiol. 1019;2012(85):e1104–9.
Lv JH, Li T, Deng XR, Li F, Song YQ, Li CR, et al. Randomized phase II study of recombinant human endostatin combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. J Clin Oncol 2015. (suppl; abstr 4035).
Ren TJ, Shan FX, Hou JF, Xue Q. Clinical observation of XELOX regimen combined with Endostar in the treatment of advanced biliary cancers. Chin J Oncol Prev Treat. 2015;7(1):41–4.
Li R, Sk Qin, Liu XF, Gong XL, Hua HQ, Wang L, et al. Preliminary observation of GEMOX regimen combined with recombinant human endostatin in the treatment of advanced biliary cancers. Chin Clin Oncol. 2014;5:430–4.
Su A, Zhang J, Pan ZH, Zhou QM, Lv X. Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14(3):1841–6.
Zhang C, Deng WY, Li N, Xu YF, Zhang YP, Wei C, et al. Clinical observation on treatment of advanced ovarian cancer with different routes of administration. Cancer Res Prev Treat. 2016;43(1):54–7.
Ke QH, ZhouSQ HuY, Liu Z, Zhang WT, Su XY, et al. Short-term efficacy of recombinant human endostatin (Endu) combined with radiotherapy in the treatment of 48 cases of advanced cervical cancer. J Mod Oncol. 2011;19(10):2066–8.
Ke QH, Zhou SH, Du F, Huang M, Luo F, Lei Y, et al. Simultaneous radiotherapy and chemotherapy combined with recombinant human endostatin in the treatment of 52 cases of advanced cervical cancer. Pract J Cancer. 2012;27(4):373–5.
Nong XS, Huang XS, Mo YF, Liang D. Short-term efficacy of Endostar combined with gemcitabine in the treatment of advanced cervical cancer. J Guangxi Med Univ. 2015;32(4):646–8.
Xu M, Xu CX, Bi WZ, Song ZG, Jia JP, Chai W. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. 2013;57(1):111–5.
Xu HR, Li B, Huang Z, Zhang Q, Niu XH. A prospective, concurrent controlled non - randomized clinical study of chemotherapy combined with recombinant human endostatin in the treatment of stage IIB osteosarcoma. Chin Clin Oncol. 2013;18(5):421–5.
Yan HL, Zhang ZC, Yang QC, Qin S, Dong Y. A prospective, non-randomized clinical study of recombinant human endostatin combined with chemotherapy in the treatment of osteosarcoma. Prog Mod Biomed. 2015;15(25):4866–71.
Zhang LP, Liao XY, Xu YM, Yan LJ, Yan GF, Wang XX, et al. Efficacy and safety of endostar combined with chemotherapy in patients with advanced soft tissue sarcomas. Asian Pac J Cancer Prev. 2013;14(7):4255–9.
Huang XF, Qu Z, Hu W, Zhang N, Wang YF, Wang Y, et al. Treatment of metastatic soft tissue sarcoma with recombinant human endostatin combined with chemotherapy Bed observation. J Mod Oncol. 2015;23:3489–92.
Xing P, Zhang J, Yan Z, Zhao G, Li X, Wang G, et al. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.13545.
Li Y, Zhang JP, Wang ZW, Zhang XZ, Zhou WK. Clinical study of recombinant human vascular endothelin combined with temozolomide in the treatment of recurrent high-grade gliomas. Chin J Brain Dis Rehabil (Electron Ed). 2014;2:8–11.
Zhang JP, Teng Y, Li C. Recombinant human endostatin combined with cytotoxic drugs to rescue chemotherapy for recurrence of glioblastoma. Chin J New Drugs Rem. 2015;4:310–4.
Li N, Jin ZL, Liu ZJ, Wang J, Li K. Recombinant human endostatin injection combined with chemotherapy for multi-cycle treatment of advanced non-small cell lung cancer. Chin J Oncol. 2011;33(12):937–42.
Hu W, Fang J, Nie J, Dai L, Zhang J, Chen XL, et al. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced non small cell lung cancer. Medicine (Baltimore). 2016;95(28):e4183.
Hansma AH, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G, et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol. 2005;16(10):1695–701.
Huang Y, Yang Y, Zhao H, Ma YX, Zou QF, Zhang L. Phase I study of continuous intravenous infusion of rh-endostatin combined with pemetrexed and carboplatin in advanced NSCLC. J Thorac Oncol. 2015;10(9):S2–315.
Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, et al. Gene therapy with the angiogenesis inhibitor endostatin in an orthotopic lung cancer murine model. Hum Gene Ther. 2009;20(2):103–11.
Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010;136(8):1201–11.
Li N, Zheng D, Wei X, Jin Z, Zhang C, Li K. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol. 2012;138(7):1131–44.
Peng F, Xu Z, Wang J, Chen YY, Li Q, Zuo YF, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 2012;7(4):e34646.
Jiang XD, Dai P, Qiao Y, Wu J, Song DA, Li SQ. Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clin Transl Oncol. 2012;14(6):437–43.
Huang MJ, Yu M, Zhang K, Li YY, Liu HM, Li WJ, et al. Early CT perfusion changes and the outcome of antiangiogenic therapy and chemotherapy in patients with advanced primary lung adenocarcinoma. J Clin Oncol. 2016;34(suppl; abstr e20543).
Wu CM, Ji JY, Shi X, Wu M, Deng G. Application of CT perfusion imaging in evaluation of therapeutic effect of osteosarcoma. Chin J Med Imaging Technol. 2011;27(6):1272–5.
Huang C, Wang X, Wang J, Lin L, Liu ZJ, Xu WJ, et al. Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor. Thorac Cancer. 2014;5(5):438–46.
Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009;27(3):404–10.
Zhang CC, Wang J, Li K. Evaluation of the efficacy of anti-angiogenesis: how far is the new standard? Chin Clin Oncol. 2011;10:951–5.
Bouvier CA, Gaynor E, Cintron JR, Bernhardt B, Spaet TH. Circulating endothelium as an indication of vascular injury. Thromb Diath Haemorrh. 1970;40(Suppl.):163–8.
Mancuso P, Bertolini F. Circulating endothelial cells as biomarkers in clinicaloncology. Microvasc Res. 2010;79(3):224–8.
Wang J, Xiao J, Wei X, Wang L, Lin L, Liu Z, et al. Circulating endothelial cells and tumor blood volume as predictors in lung cancer. Cancer Sci. 2013;104(4):445–52.
Chu TQ, Ding H, Garfield DH, Gu AQ, Pei J, Du WD, et al. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study. J Thorac Oncol. 2012;7(12):1781–9.
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011;71(16):5512–21.
Twombly R. First clinical trials of endostatin yield lukewarm results. J Natl Cancer Inst. 2002;94(20):1520–1.
Shi HL, Xu LY, Liu Z. Clinical study of recombinant human endostatin (YH-16) injection in the treatment of advanced non-small cell lung cancer. Chin J Lung Cancer. 2004;7(4):325–8.
Yang L, Wang JW, Tang ZM, Liu XW, Huang J, Li ST, et al. Phase I Clinical study of recombinant human endostatin. Chin J New Drugs. 2004;13(6):548–53.
Wang WJ, Sun Y, Liu Y, Yu QT, Zhang YP, Li K, et al. Recombinant human endostatin combined with NP regimen for the treatment of advanced NSCLC in a randomized, double-blind, controlled, multicenter phase III clinical study. Chin J Lung Cancer. 2005;8(4):283–90.
Yang L, Wang JW, Sun Y, Zhu YZ, Liu XQ, Li WL, et al. Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer[J]. Chin J Oncol. 2006;28(2):138–41.